Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,883
Employees75,883
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,883
Employees75,883

NVS Key Statistics

Market cap
278.62B
Market cap278.62B
Price-Earnings ratio
17.81
Price-Earnings ratio17.81
Dividend yield
2.49%
Dividend yield2.49%
Average volume
1.45M
Average volume1.45M
High today
$133.18
High today$133.18
Low today
$131.39
Low today$131.39
Open price
$132.39
Open price$132.39
Volume
1.74M
Volume1.74M
52 Week high
$134.00
52 Week high$134.00
52 Week low
$96.06
52 Week low$96.06

Stock Snapshot

With a market cap of 278.62B, Novartis(NVS) trades at $128.17. The stock has a price-to-earnings ratio of 17.81 and currently yields dividends of 2.5%.

During the trading session on 2025-11-18, Novartis(NVS) shares reached a daily high of $133.18 and a low of $131.39. At a current price of $128.17, the stock is -2.5% higher than the low and still -3.8% under the high.

Trading activity shows a volume of 1.74M, compared to an average daily volume of 1.45M.

Over the past 52 weeks, Novartis(NVS) stock has traded between a high of $134.00 and a low of $96.06.

Over the past 52 weeks, Novartis(NVS) stock has traded between a high of $134.00 and a low of $96.06.

NVS News

Benzinga 5d
Novartis' Investigational Medicine Shows Potent Activity Against Drug-Resistant Malaria Strains

Novartis AG (NYSE:NVS) released data on Thursday from the KALUMA Phase 3 study for the new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum). GanL...

Novartis' Investigational Medicine Shows Potent Activity Against Drug-Resistant Malaria Strains
Seeking Alpha 5d
Novartis says novel antimalarial succeeded in late-stage trial

Novartis (NVS) (OTCPK:NVSEF) has announced that its next-generation malaria treatment, KLU156 (GanLum), developed with Swiss nonprofit Medicines for Malaria Ven...

Novartis says novel antimalarial succeeded in late-stage trial
TipRanks 5d
Novartis announces Phase III trial for KLU156 met primary endpoint

Novartis (NVS) announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156. The novel non-artemisinin antimalarial, which was dev...

Analyst ratings

57%

of 28 ratings
Buy
25%
Hold
57.1%
Sell
17.9%

More NVS News

TipRanks 5d
Novartis Stock Doesn’t Suck as it Hails Generational Anti-Malaria Drug

Shares in Swiss pharmaceutical giant Novartis (NVS) were looking healthier today after hailing a generational breakthrough in the battle against the deadly mala...

Nasdaq 7d
Novartis AG Basel Reaches Analyst Target Price

In recent trading, shares of Novartis AG Basel (Symbol: NVS) have crossed above the average analyst 12-month target price of $127.00, changing hands for $127.11...

Novartis AG Basel Reaches Analyst Target Price
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.